Recent research have centered on the intersection of glucagon-like peptide-1|glucose-dependent insulinotropic polypeptide|GCGR stimulant therapies and DA communication. While GLP agonists are widely employed for managing type 2 diabetes, their unexpected impacts on reward circuits, specifically governed by dopamine networks, are attracting signific